Navigation Links
Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
Date:4/21/2009

ost frequent pathogens infecting bronchiectasis patients is Pseudomonas aeruginosa, which is associated with increased sputum production, more extensive bronchiectasis, more hospitalizations, and reduced quality of life.

The disease is often misdiagnosed and mistaken for asthma or pneumonia. There is currently no drug specifically approved for the treatment of bronchiectasis or the associated lung infections in the U.S.

About Arikace (liposomal amikacin for inhalation)

Arikace is a form of the antibiotic amikacin, which is enclosed in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), neutrally-charged liposomes that enable penetration of the biofilm and are highly efficient, with a very low lipid-to-drug ratio (0.65). Arikace can be delivered through nebulization, which enables the small aerosol droplet size (1 to 5 microns) to facilitate more effective distribution in the lungs. In addition to this clinical study in non-CF bronchiectasis patients with Pseudomonas lung infections, clinical development has been initiated in CF patients with Pseudomonas lung infections, with positive Phase II results reported in June 2008. Arikace has been granted orphan drug status in the United States by the FDA, and has received an orphan drug designation in Europe by the European Medicines Agency for the treatment of Pseudomonas infections in patients with CF.

About PARI Pharma and the eFlow(R) Electronic Nebulizer

Arikace is delivered by an Investigational eFlow Nebulizer System developed by PARI Pharma GmbH. The I
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... MILAN (PRWEB) March 28, 2015 ... thought-leaders in the fields of osteoporosis, osteoarthritis and ... on Osteoporosis, it may be the first time ... educational research forum that the hot-button topic is ... Based on the well-accepted scientific principles of Wolff’s ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... surgery experiences re-injury, according to research presented today at ... ) Specialty Day. The study examined the long term ... younger. , “We examined survey data from 242 ... noted lead author Justin P. Roe, MBBS, FRACS, from ...
(Date:3/28/2015)... 2015 Genomic medicine experts have sequenced ... for the first time, key information for understanding and ... the newly posted story on the Surviving Mesothelioma ... British Columbia, the British Columbia Cancer Agency, and PhenoPath ... underlying molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... 24 Many religions teach that selflessly "doing unto ... , , A growing body of ... promoting health and general well-being--research that will be outlined more fully ... Research Says." (1) , , ...
... fertility solutions,agencies today announced the launch of a unique cooperative ... donors dropping out before the,retrieval process is completed. , ... is an initiative by The Center for Egg,Options (CEO), Northbrook, ... Egg donation is an ...
... institution , ... Washington, DC (Vocus) November 24, 2008 ... , dedicated new research facilities today, increasing the space of one ... square feet. , , , , ,Elected officials and scientific leaders ...
... For over a decade Ochsner Health System,has enjoyed ... in improved patient care, cost savings and increased revenues ... of New Orleans have,seen more than their share of ... have left the greater New Orleans hospital infrastructure,badly damaged. ...
... its January 1,2009 opening, San Francisco Village-Northside (SFV-N) announces ... (IOA). , SFV-N ... older adults and those who care for them live ... they wish or are,able. A model that is sweeping ...
... think of the holidays,as a time for joy and togetherness. ... emotionally trying time. The buildup of the,pressure to create the ... negative consequences, such as depression,anxiety and substance dependency. , ... ) , "During the ...
Cached Medicine News:Health News:Conferees to Explore How Religious Practice Reaps Health 2Health News:Conferees to Explore How Religious Practice Reaps Health 3Health News:Three Chicago Area Fertility Agencies Launch 'Shared Risk' Program 2Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News:Under Wraps: Uncovering the Secrets and Lies of the Holiday Season 2
(Date:3/27/2015)... HILL, N.C. , March 27, 2015 ... is essential to meeting challenges in clinical development, market ... face tighter regulations, the Medical Affairs function is expected ... by mature markets. According to research ... study participants have a group dedicated to Medical Affairs. ...
(Date:3/27/2015)... 2015 Object recognition technology has a unique ... elderly. The VelaSense ® mobile platform ... independent, productive and fulfilling lives. VelaSense ® will ... to identify objects from a one million object database, ... object databases for personal use. Visus ...
(Date:3/27/2015)... AUGUSTA, Ga. , March 27, 2015  Holographic ... innovator in the field of holographic medical imaging, is ... of its Kickstarter campaign. Launching on April 20 th ... Voxbox and Voxbox Pro. The 8-inch and 22-inch displays ... at home for the first time. In addition to ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
... 2007 -,GlaxoSmithKline (LSE and NYSE:GSK) and Adolor ... and,provided an update on the clinical development ... 3, double blind, placebo-controlled (12,month) study, was ... of alvimopan 0.5 mg twice daily in ...
Cached Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: